Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine (Q46230871)

From Wikidata

Jump to navigation Jump to search

scientific article published on 27 September 2011

Language	Label	Description	Also known as
English	Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine	scientific article published on 27 September 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21953939

Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21953939

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21953939

5

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21953939

Francesco Ortuso

6

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21953939

Philippe Flandre

11

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21953939

Anne-Geneviève Marcelin

15

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21953939

Francesca Ceccherini-Silberstein

4

object named as

Francesca Ceccherini-Silberstein

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

Federica Forbici

object named as

Federica Forbici

8

0 references

object named as

Ada Bertoli

7

0 references

Maria M Santoro

object named as

Maria Mercedes Santoro

9

0 references

object named as

Stefano Alcaro

1

0 references

Carlo Federico Perno

16

object named as

Carlo Federico Perno

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

13

object named as

Diane Descamps

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

Bernard Masquelier

12

object named as

Bernard Masquelier

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21953939

Valentina Svicher

18

object named as

Valentina Svicher

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21953939

3

object named as

Anna Artese

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21953939

10

object named as

Lucia Parrotta

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21953939

17

object named as

Tobias Sing

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21953939

author name string

Vincent Calvez

14

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21953939

publication date

27 September 2011

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21953939

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21953939

6

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21953939

12

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21953939

2203-2213

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21953939

Inhibitors of HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Antiviral drugs in current clinical use.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Another ten stories in antiviral drug discovery (part C): "Old" and "new" antivirals, strategies, and perspectives

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Molecular basis of human immunodeficiency virus drug resistance: an update.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Protein-nucleic acid interactions and DNA conformation in a complex of human immunodeficiency virus type 1 reverse transcriptase with a double-stranded DNA template-primer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

High resolution structures of HIV-1 RT from four RT-inhibitor complexes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009).

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Human immunodeficiency virus reverse transcriptase and protease sequence database

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Detecting and understanding combinatorial mutation patterns responsible for HIV drug resistance

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Computational methods for the design of effective therapies against drug resistant HIV strains

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Understanding the basis of resistance in the irksome Lys103Asn HIV-1 reverse transcriptase mutant through targeted molecular dynamics simulations

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

The search for potent, small molecule NNRTIs: A review.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

A study of the binding energies of efavirenz to wild-type and K103N/Y181C HIV-1 reverse transcriptase based on the ONIOM method

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective against Wild-Type and Drug-Resistant HIV-1 V

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

21 January 2018

HIV Drug Resistance

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

7 January 2021

based on heuristic

inferred from DOI database lookup

Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

7 January 2021

based on heuristic

inferred from DOI database lookup

Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100362

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CMDC.201100362

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21953939

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/21953939

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46230871&oldid=2100556589"